AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 290: R145-R153, 2006. First published December 1, 2005; doi:10.1152/ajpregu.00405.2005
0363-6119/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/1/R145    most recent
00405.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Busija, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Busija, D. W.

CALL FOR PAPERS
Metabolic Syndrome

Impaired endothelin-induced vasoconstriction in coronary arteries of Zucker obese rats is associated with uncoupling of [Ca2+]i signaling

Prasad V. G. Katakam, James A. Snipes, Christina D. Tulbert, Keita Mayanagi, Allison W. Miller, and David W. Busija

Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, North Carolina

Submitted 7 June 2005 ; accepted in final form 27 September 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Although insulin resistance (IR) is a major risk factor for coronary artery disease, little is known about the regulation of coronary vascular tone in IR by endothelin-1 (ET-1). We examined ET-1 and PGF2{alpha}-induced vasoconstriction in isolated small coronary arteries (SCAs; ~250 µM) of Zucker obese (ZO) rats and control Zucker lean (ZL) rats. ET-1 response was assessed in the absence and presence of endothelin type A (ETA; BQ-123), type B (ETB; BQ-788), or both receptor inhibitors. ZO arteries displayed reduced contraction to ET-1 compared with ZL arteries. In contrast, PGF2{alpha} elicited similar vasoconstriction in both groups. ETA inhibition diminished the ET-1 response in both groups. ETB inhibition alone or in combination with ETA blockade, however, restored the ET-1 response in ZO arteries to the level of ZL arteries. Similarly, inhibition of endothelial nitric oxide (NO) synthase with N{omega}-nitro-L-arginine methyl ester (L-NAME) enhanced the contraction to ET-1 and abolished the difference between ZO and ZL arteries. In vascular smooth muscle cells from ZO, ET-1-induced elevation of myoplasmic intracellular free calcium concentration ([Ca2+]i) (measured by fluo-4 AM fluorescence), and maximal contractions were diminished compared with ZL, both in the presence and absence of L-NAME. However, increases in [Ca2+]i elicited similar contractions of the vascular smooth muscle cells in both groups. Analysis of protein and total RNA from SCA of ZO and ZL revealed equal expression of ET-1 and the ETA and ETB receptors. Thus coronary arteries from ZO rats exhibit reduced ET-1-induced vasoconstriction resulting from increased ETB-mediated generation of NO and diminished elevation of myoplasmic [Ca2+]i.

insulin resistance; endothelial nitric oxide synthase

COMPELLING SCIENTIFIC EVIDENCE has established that individuals with impaired glucose tolerance [prediabetes or insulin resistance (IR)] and/or obesity are at a substantially increased risk of type 2 diabetes (6). Clinical evidence has also identified IR as an independent risk factor for hypertension, coronary artery disease, and stroke (27, 39a). However, the mechanisms underlying the coronary artery disease in IR have not been thoroughly investigated.

It is believed that impaired ability to vasodilate and/or an enhanced sensitivity to vasoconstrictor agonists underlie the vascular dysfunction associated with IR. Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor peptide, plays an important role in regulation of vascular tone in the coronary circulation. The actions of ET-1 are mediated by two major receptors, endothelin type A (ETA) and type B (ETB), which are present on vascular smooth muscle (VSM) cells and endothelial cells (5, 33). Vascular contraction induced by ET-1 is predominantly mediated by activation of VSM cell ETA receptors but may also occur by stimulation of VSM cell ETB receptors (5, 33). ET-1 regulates the contraction of VSM cells primarily by increasing intracellular Ca2+ concentration ([Ca2+]i) via opening various Ca2+ channels (5, 33). In addition, ET-1 also modulates the contraction through activating the Ca2+-independent RhoA/Rho-kinase pathway (14). Activation of endothelial ETB receptors results mostly in increased endothelial nitric oxide (NO) synthase (eNOS) activity and release of NO.

Abnormal ET-1 activity has been implicated in the pathogenesis of cardiovascular diseases associated with diabetes. However, studies of ET-1 activity in coronary arteries were mostly limited to models of diabetes (25, 39, 40). ET-1 regulation of coronary circulation, in the setting of IR, has not been adequately studied. Hyperinsulinemia, pathognomonic of IR, has been shown to promote the expression of ET-1 (30) and its receptors (17). Moreover, we previously reported enhanced insulin-induced vasoconstriction in young male Zucker obese (ZO) rats compared with the lean (ZL) controls, a widely accepted model of IR (22). We hypothesized that hyperinsulinemia associated with IR promotes enhanced activity of ET-1 in ZO arteries. Therefore, we examined the role of ET-1 in coronary vascular dysfunction in 12-wk-old ZO and ZL by evaluating 1) the vascular response to ET-1 and PGF2{alpha}; 2) the contribution of ETA and ETB receptors to ET-1 responses; 3) the interaction of NO and ET-1 in regulation of coronary vascular tone; 4) the expression of ET-1, ETA, and ETB receptors; and 5) the role of VSM cell [Ca2+]i in ET-1-induced contraction and the relationship between [Ca2+]i and contractility of VSM cells.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The experimental protocol was approved by the Animal Care and Use Committee of Wake Forest University Health Sciences. All experiments complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Experiments were performed on male 12- to 13-wk-old ZL (n = 16) and ZO (n = 20) rats (Harlan, Indianapolis, IN). Animals were fed standard rat diet and drank tap water ad libitum.

Isolation and cannulation of the arteries. These methods have been described previously (13, 21, 22). Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg ip) and anticoagulated with heparin (500 U ip). The heart was removed after thoracotomy and placed in a chilled oxygenated modified Krebs-Ringer bicarbonate solution concentration (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 11.1 dextrose. SCA ({approx}250 µm diameter) from the septum and/or the epicardium were isolated from the surrounding perivascular tissue and removed. A section of the small coronary artery (SCA) was transferred to a vessel chamber, mounted between two glass micropipettes, and secured with 10-0 ophthalmic suture. The vessel bath was mounted on an inverted microscope with a video camera attached. Oxygenated and warmed (20% O2-5% CO2-75% N2 at 37°C) Krebs solution was circulated continuously through the vessel bath. The lumen of the artery was filled with Krebs solution; one micropipette was clamped off, and the other was connected to a pressure servocontrol (Living Systems, Burlington, VT) to maintain a constant intraluminal pressure of 60 mmHg. Drugs were added abluminally to the bath solution. Only one concentration-response experiment was performed per arterial segment; however, several arterial segments were taken from each rat. The video camera on the microscope was connected to a TV monitor and also to a video dimension analyzer (Living Systems) that measures intraluminal diameter. Vascular responses were recorded on a calibrated chart paper recorder for analysis.

Vascular reactivity experiments. Coronary arteries were allowed to equilibrate for 30 min in the tissue bath. Subsequently, concentration-response studies to ET-1 (10-12–10–8 M) were performed. To evaluate the role of NO in the vascular response to ET-1, arteries were pretreated for a period of 30 min with N{omega}-nitro-L-arginine methyl ester (L-NAME) (100 µM), an inhibitor of eNOS. To evaluate the role of the ETA or ETB receptors in the vascular response to ET-1, arteries were pretreated for a period of 30 min with specific inhibitors BQ-123 (1 µM) or BQ-788 (1 µM), respectively, or both. To establish the specificity of ET-1 activity, responses to PGF2{alpha} (10–9–10–5 M), a vasoconstrictor prostanoid, was also determined. At the end of each experiment, the quality of vascular preparation was tested by administration of ACh (10–5 M), an endothelium-dependent vasodilator, followed by sodium nitroprusside (10–4 M), an exogenous NO donor. Data were reported as %constriction (the change in diameter for each concentration of ET-1 administered expressed as %baseline diameter).

Western blot analysis. Equal amounts of protein for each sample were separated by 4–20% SDS-PAGE and transferred onto a PVDF sheet (Polyscreen PVDF; PerkinElmer Life Sciences, Boston, MA). Membranes were incubated in a blocking buffer (Tris-buffered saline, 0.1% Tween 20, 5% skim-milk powder) for 1 h at room temperature, and then blots were incubated with monoclonal anti-ETA (1:3,000; BD Transduction Laboratories) or monoclonal anti-{beta}-actin (1:25,000; Sigma) antibodies overnight at 4°C. Membranes were then washed three times in Tris-buffered saline with 0.1% Tween 20 and incubated for 1 h in the blocking buffer with anti-mouse IgG (1:10,000; Jackson ImmunoResearch Laboratories, West Grove, PA) conjugated to horseradish peroxidase. Final reaction products were visualized using enhanced chemiluminescence (SuperSignal West Pico; Pierce, Rockford, IL) and recorded on X-ray film. The bands were scanned and the densities of the bands were quantitated by using FotoDyne, (FOTO/Analyst PC Image and Image J). Subsequently, data were expressed by normalizing the immunoblot band density of the protein of interest to the corresponding band density of {beta}-actin.

RT-PCR. Total RNA was obtained from isolated SCA using the SV Total RNA Isolation System (Promega, Madison, WI), and RT-PCR experiments were carried out as described previously (23). Expression of ET-1, ETA receptor, and ETB receptor mRNA was analyzed using specific primers (Table 1). Expected lengths of the RT-PCR products were 500, 416, and 386 base pairs, respectively. {beta}-Actin primers (Promega) were also included in the RT-PCR reaction to normalize the RT-PCR results with an expected product length of 285 base pairs. Each PCR reaction was repeated at least three times. The number of PCR cycles varied according to the expression level of the target gene. An appropriate number of cycles was determined to ensure that PCR was taking place in the linear range, to guarantee a proportional relationship between input RNA and densitometric readout.


View this table:
[in this window]
[in a new window]
  		Table 1. Sequences of primers

 
Isolation of vascular smooth muscle cells. SCAs were isolated as described in Isolation and cannulation of the arteries. As a positive control, cerebral arteries from ZO and ZL rats that displayed identical contraction to ET-1 were also evaluated for elevation of VSM cell [Ca2+]i. Cerebral arteries (250–300 µM) were isolated as described previously (8). Briefly, brains were removed after decapitation of the rats and immediately placed in cold, oxygenated, modified Krebs-Ringer bicarbonate solution (in mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4, 1.18 KH2PO4, 24 NaHCO3, 0.026 EDTA, 1.6 CaCl2, and 5.5 glucose. With the aid of a dissecting microscope, middle, anterior, and posterior cerebral arteries and basilar arteries were carefully isolated. All the arteries were transferred to a vessel chamber and mounted onto a glass micropipette, and the blood inside the arteries was flushed out by careful infusion with cold Krebs solution. To measure the ET-1-induced changes in fluo-4 AM fluorescence, single smooth muscle cells were prepared freshly as described by Giulumian and colleagues (12, 28). Briefly, isolated SCAs and cerebral arteries were placed in dissociation medium (in mM): 110 NaCl, 5 KCl, 2 MgCl2, 0.16 CaCl2, 10 HEPES, 10 NaHCO3, 0.5 KH2PO4, 0.5 NaH2PO4, 0.49 EDTA, 10 taurine, and 10 glucose (pH 6.9) containing albumin (4 mg/ml) with papain (1.52 mg/ml) and dithiothreitol (0.54 mg/ml). Cells were dispersed for 30 min in a shaking water bath at 37°C followed by mild trituration. The solution was centrifuged at 1,000 g for 12 min, and the pellet was resuspended in dissociation medium to obtain freshly dispersed smooth muscle cells.

[Ca2+]i imaging and data analysis. VSM cells were loaded for 30 min at room temperature with 0.5 µM fura-4 AM admixed with equal volume of Pluronic F-127 (0.1%). Subsequently, cells were washed twice with dissociation medium and resuspended in normal Ringer solution (in mM: 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES; pH 7.4). The cells were imaged using a Zeiss LSM 510 laser scanning microscope (Carl Zeiss, Jena, Germany). VSM cells were placed in a four-chambered coverglass (Nalge Nunc, Naperville, IL) and mounted on the stage of an Axiovert inverted microscope. The excitation beam of 488 nm was produced by an argon laser, attenuated in intensity with an acoustooptical tunable filter, and delivered to the specimen via a Zeiss Apochromat x63 water immersion objective. Emitted fluorescence was captured at wavelengths >510 nm using LSM 510 software (version 2.01; Carl Zeiss, Jena, Germany) running on a Windows XP work station. During a time series protocol, x-y axes 2-D images (typically 50–80 images per series; image depth of 8 bits) 512 x 512 pixels, were taken every 5 s. All experiments were done at room temperature (20–23°C). Responses to ET-1 (10–9 and 10–8 M) and potassium chloride (KCl; 0.5 mM) were assessed in the presence and absence of L-NAME (100 µM). Images were processed and analyzed using the software provided by Carl Zeiss. Global [Ca2+]i was estimated across the entire cell by selecting the regions of interest in x-y mode and measuring the fluorescence. First, the average fluorescence of the baseline series of images (no solutions added) and test series at peak response (when ET-1 or KCl was added) were obtained. The test series average fluorescence was expressed as %change from the baseline series average fluorescence. The longitudinal length of an individual VSM cell was measured using open polyline drawing mode in the overlay function tool of Zeiss LSM Image Browser (Jena, Germany). The %change in length of VSM cells was calculated in the same manner as the fluorescence measurements. Data were expressed as means ± SE for the number of cells (n) analyzed. On any given day, VSM cells from a pair of ZL and ZO rats were prepared and the experiments were conducted simultaneously under the same conditions.

Chemicals. All chemicals used in this study were obtained from Sigma (St. Louis, MO). Fluo-4 AM and Pluronic F-127 were purchased from Molecular Probes (Eugene, OR). Fluo-4 AM stock solution was made in DMSO, and aliquots were stored at approximately –20°C and protected from light.

Data analysis. All data are reported as means ± SE. All statistical comparisons for concentration response experiments were performed using ANOVA with repeated measures followed by Tukey's post hoc test. The criteria for significance was P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Vascular reactivity. The resting intraluminal diameter of SCAs did not differ between ZL (249 ± 8 µm, n = 45) and ZO (246 ± 7 µm, n = 48) rats. In ZL arteries, ET-1 induced a concentration-dependent vasoconstriction with a maximal constriction of 82 ± 2% (n = 9; Fig. 1). Similarly, ET-1 induced a dose-dependent vasoconstriction in ZO arteries, but the maximal constriction was significantly reduced to 58 ± 3% (n = 15, P < 0.05; Fig. 1).



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1. Cumulative concentration-response experiments to endothelin-1 (ET-1; 10–12–10–8 M) in small coronary arteries (SCAs) from Zucker lean (ZL) and Zucker obese (ZO) rats with and without N{omega}-nitro-L-arginine methyl ester (L-NAME; 100 µM) pretreatment. *,{psi}Statistically significant difference (P < 0.05) in vasoconstriction to ET-1 compared with the baseline response in ZL and ZO arteries, respectively.

 
Pretreatment of arteries with L-NAME resulted in a constriction in both ZL (4 ± 1%, n = 8) and ZO arteries; however, it was significantly greater in ZO arteries (12 ± 2%, n = 5, P < 0.05). In the presence of L-NAME, significantly increased contraction was observed at all concentrations of ET-1 in ZO arteries, whereas enhanced contraction to ET-1 was observed at 10–10 M in ZL arteries (Fig. 1). The maximal constriction to ET-1 was significantly enhanced only in arteries from ZO rats (74 ± 5%, n = 5; P < 0.05 vs. baseline) compared with ZL arteries [82 ± 4%, n = 8; P = not significant (NS) vs. baseline]. In contrast, the EC50 of ET-1 response was significantly decreased in both groups, indicating enhanced sensitivity to ET-1 in the presence of L-NAME (Table 2).


View this table:
[in this window]
[in a new window]
  		Table 2. Vascular response to ET-1

 
Pretreatment of the arteries with BQ-123 did not affect the baseline diameter in either group (data not shown). However, BQ-123 significantly inhibited the ET-1 response in both ZL (44 ± 7%, n = 7) and ZO (11 ± 5%, n = 6) arteries by reducing the maximal constriction (P < 0.05; Fig. 2) and increasing the EC50 (P < 0.05; Table 2) compared with corresponding baseline responses. In contrast, BQ-788 significantly reduced the baseline diameter in ZO arteries (2.2 ± 0.8%; n = 7, P < 0.05) compared with ZL (0 ± 0.6%; n = 7). Furthermore, BQ-788 significantly enhanced the constriction to ET-1 only at 10–8 M concentration in ZO arteries, whereas the ET-1 response in ZL arteries was unaffected. The maximal constriction to ET-1 in BQ-788-treated arteries was 72 ± 3% in ZO (n = 7; P < 0.05 vs. baseline) and 77 ± 3% in ZL (n = 7; Fig. 2). BQ-788 did not change the EC50 of ET-1 response in both groups (Table 2). Pretreatment of arteries with BQ-123 and BQ-788 together reduced the contraction to ET-1 in ZL arteries, whereas ZO arteries were unaffected. The maximal contraction to ET-1 was 42 ± 9% in ZL (n = 6; P < 0.05 vs. baseline) and 42 ± 5% in ZO arteries (n = 7; P = NS vs. baseline). In contrast, the EC50 of ET-1 response was significantly increased in the presence of BQ-123 and BQ-788 in both groups compared with baseline (Table 2).



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 2. Cumulative concentration-response experiments to ET-1 (10–12–10–8 M) in SCAs from ZL and ZO rats. Arteries were pretreated with ETA receptor inhibitor BQ-123 (1 µM), ETB receptor inhibitor BQ-788 (1 µM), or both. *,{psi}Statistically significant difference (P < 0.05) in vasoconstriction to ET-1 compared with the baseline response in ZL and ZO arteries, respectively.

 
PGF2{alpha} induced contraction of SCA in a dose-dependent manner. Although ZO arteries (23 ± 4%, n = 8) showed a tendency toward enhanced maximal contraction to PGF2{alpha} compared with ZL arteries (33 ± 4%, n = 8), the difference was not statistically significant (Fig. 3).



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 3. Cumulative concentration-response experiments to PGF2{alpha} (10–9–10–5 M) in SCAs from ZL and ZO rats.

 
Expression of ET-1 and ET receptors. Western blot analysis with specific antibodies revealed that ZO and ZL arteries exhibit equal expression of ETA receptors. Densities of respective immunoreactive bands, normalized to {beta}-actin and expressed in arbitrary units, were 0.64 ± 0.17 in ZO arteries (n = 8) and 0.67 ± 0.14 in ZL arteries (n = 8, P = NS; Fig. 4B). In addition, RT-PCR experiments showed that expression of ET-1 mRNA was similar in the ZO and ZL arteries; densities of bands normalized to {beta}-actin and expressed in arbitrary units, were 0.4 ± 0.02 (n = 6) in ZO and 0.35 ± 0.04 (n = 5) in ZL (P = NS). Similarly, densities of normalized bands of ETA and ETB receptor mRNAs were 0.88 ± 0.05 and 0.82 ± 0.05 (n = 6 each) in ZO and 0.75 ± 0.07 and 0.79 ± 0.07 (n = 5 each) in ZL, respectively (P = NS; Fig. 5B).



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 4. A: images of Western blots using antibodies directed against the ETA receptor and {beta}-actin in isolated SCAs of ZO and ZL arteries. B: each lane was loaded with equal amounts of protein, and densities of the immunoreactive bands were normalized to {beta}-actin. Normalized intensities of the immunoreactive bands were similar in ZO and ZL arteries.

 


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 5. A: detection of ET-1, ETA receptor, and ETB receptor mRNA with RT-PCR in SCAs of ZO and ZL rats with corresponding {beta}-actin mRNA. B: intensities of the mRNA bands normalized to those of corresponding {beta}-actin were similar in ZO and ZL arteries.

 
[Ca2+]i measurement. ET-1 induced a concentration-dependent elevation of fluo-4 AM fluorescence in VSM cells of both ZO and ZL arteries. The elevation in fluorescence intensity in response to ET-1 or KCl was associated with contraction of the VSM cells. Fig. 6A shows a typical response of VSM cells at baseline and after administration of ET-1 and KCl. Maximal increase in [Ca2+]i to 10–9 M ET-1 was 41 ± 11% in ZL (n = 22) compared with 12 ± 8% in ZO (n = 21, P < 0.05; Fig. 6B). Similarly, maximal increase in [Ca2+]i to 10–8 M ET-1 was 69 ± 11% in ZL (n = 15) compared with 28 ± 9% in ZO (n = 19, P < 0.05; Fig. 6B). In addition, maximal contraction of VSM cells in response to ET-1 was significantly reduced in ZO (22 ± 4%, n = 22; P < 0.05) compared with ZL (46 ± 2%, n = 21; Fig. 6C). In the presence of L-NAME, maximal increase in [Ca2+]i to ET-1 was 75 ± 14% in ZL (n = 18) compared with 36 ± 12% in ZO (n = 27, P < 0.05). Similarly, in the presence of L-NAME, maximal contraction of VSM cells in response to ET-1 was significantly reduced in ZO (15 ± 4%, n = 19; P < 0.05) compared with ZL (39 ± 5%, n = 18; Fig. 6C). However, there was no significant difference in either peak increase in [Ca2+]i or maximal decrease in VSM cell length in response to ET-1 between L-NAME-treated and -untreated cells. In addition, L-NAME (10 and 100 µM) pretreatment alone had no effect on [Ca2+]i or VSM cell length (data not shown).



View larger version (44K):
[in this window]
[in a new window]
  		Fig. 6. [Ca2+]i imaged in fluo-4 AM-loaded, freshly dispersed vascular smooth muscle (VSM) cells from SCAs of ZL and ZO arteries. A: fluo-4 AM fluorescence and differential interference contrast (DIC) images of time frames from a series of x-y images of VSM cells at baseline and after ET-1 (10–10–10–8 M) and KCl (50 mM) administration are shown. Images of VSM cells (top) from ZL arteries and from ZO arteries (bottom) are shown. B: cumulative data from fluo-4 AM fluorescence measurements with the %maximal increase in [Ca2+]i of VSM cells from ZO and ZL arteries in response to ET-1 and KCl are represented in a bar graph. *Statistically significant difference (P < 0.05) compared with the corresponding response in ZL arteries. C: cumulative data from VSM cell length measurements are shown with the %maximal decrease in length in response to ET-1 in the presence and absence of L-NAME. *Significant difference (P < 0.05) in ET-1 response in untreated VSM cells of ZO arteries compared with the response of untreated VSM cells of ZL. {psi}Significant difference (P < 0.05) in ET-1 response in L-NAME-treated VSM cells of ZO arteries compared with L-NAME-treated VSM cells of ZL arteries.

 
Maximal contraction of each VSM cell was divided by the corresponding maximal increase of [Ca2+]i in response to ET-1, and the fraction was used as an index of the [Ca2+]i-contractility relationship. This index, however, was not significantly different between ZL (0.91 ± 0.16) and ZO (0.94 ± 0.22) rats. Thus a given increase in [Ca2+]i in ZO rats elicited similar contraction of the VSM cells compared with ZL, suggesting that the sensitivity of contractile apparatus to [Ca2+]i was not altered in ZO arteries. In other words, both groups of rats exhibited a linear relationship between VSM cell [Ca2+]i and contractility, indicating ET-1-induced contraction is proportional to the elevation of [Ca2+]i. In addition, maximal increase in [Ca2+]i from baseline in response to KCl was similar in ZL (74 ± 12%, n = 6) compared with ZO (86 ± 9%, n = 9, P = NS; Fig. 6B).

In VSM cells of cerebral arteries from both ZO and ZL rats, ET-1 readily induced elevation of fluo-4 AM fluorescence followed by contraction at a much lower concentration (10–10 M) compared with SCA. Figure 7A shows a typical fluo-4 AM fluorescence of VSM cells at baseline and after administration of ET-1 (10–10 M). ET-1 induced a similar elevation of [Ca2+]i in VSM cells of ZO and ZL cerebral arteries (Fig. 7). Maximal increase in [Ca2+]i from baseline in response to ET-1 was 92 ± 13% in ZL (n = 15) compared with 76 ± 10% in ZO (n = 17, P = NS; Fig. 7B) arteries. Similarly, maximal contraction in response to ET-1 was 48 ± 3% in ZL (n = 15) compared with 48 ± 3% in ZO (n = 17, P = NS; Fig. 7B) arteries. The index of [Ca2+]i-contractility relationships was also not significantly different between ZL (0.93 ± 0.33) and ZO (0.99 ± 0.35) arteries, suggesting a similar [Ca2+]i sensitivity of contractile apparatus.



View larger version (38K):
[in this window]
[in a new window]
  		Fig. 7. [Ca2+]i imaged in fluo-4 AM-loaded, freshly dispersed VSM cells from cerebral arteries of ZL and ZO arteries. A: fluo-4 AM fluorescence and DIC images of time frames from a series of x-y images of VSM cells from ZO and ZL arteries at baseline and following ET-1 (10–10 M) treatment are shown. B: cumulative data from [Ca2+]i and VSM cell length measurements showing the %maximal increase in [Ca2+]i fluorescence intensity from baseline (left) and %maximal contraction from baseline (right) of VSM cells from ZO and ZL cerebral arteries, in response to ET-1 were represented in a bar graph.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Major findings of this study are as follows: 1) ET-1-induced vasoconstriction in SCAs of ZO rats was reduced compared with ZL; 2) inhibition of NO production or ETB receptor blockade restored the contraction to ET-1 in ZO arteries; 3) studies of protein from SCAs revealed similar expression of ETA, whereas mRNA studies showed identical expression of ETA and ETB receptors and ET-1 peptide in both rat groups; 4) freshly isolated VSM cells of ZO coronary arteries exhibited reduced [Ca2+]i elevation and contraction in response to ET-1 compared with ZL arteries, suggesting the uncoupling of ET-1 receptor activation and [Ca2+]i signaling; and 5) VSM cell [Ca2+]i-contractility relationship revealed an intact Ca2+ sensitivity of the contractile apparatus in ZO arteries.

The ZO rat model has been well defined in terms of biochemistry and vascular function. We reported previously that, when on a regular diet, 12-wk-old ZO rats exhibit IR alone (hyperinsulinemia) but without overt diabetes (fasting euglycemia) (9, 10). However, the ZO rats have greater weight and display dyslipidemia characterized by elevated triglycerides and elevated total cholesterol (11). Thus ZO rats exhibit characteristics of the typical metabolic syndrome accompanying prediabetes or IR found in humans.

Previously, our vascular reactivity studies (10) of basilar artery in ZO rats found impaired vasodilation to ACh with intact vasoconstriction to ET-1. In contrast, we (22) observed that coronary arteries of ZO rats displayed normal vasodilation to ACh. Interestingly, in ZO coronary arteries, insulin-induced vasodilation was diminished, whereas vasoconstriction was enhanced (22). Thus it is apparent that vascular dysfunction associated with IR was mediated by a variety of mechanisms based on the vascular bed studied. In the present study, contrary to our hypothesis, we found that ET-1-induced vasoconstriction was reduced in the SCA of ZO rats compared with ZL rats. However, contractile response to vasoconstrictor prostanoid PGF2{alpha} was similar in ZO and ZL arteries. Thus the decreased vasoconstriction to ET-1 in ZO arteries appears to be a specific defect unique to endothelin receptors.

A majority of the studies in coronary arteries of models of diabetes reported enhanced constriction to ET-1 (25, 39, 40). In Zucker rats, ET-1-induced vasoconstriction has been examined in mesenteric (1, 17, 38), basilar (9, 20), skeletal muscle (37) arteries, and thoracic aorta (17–19, 38, 43). Conflicting findings reported either an increased or normal contraction to ET-1 in ZO arteries. Similar variation was also observed in response to vasodilators with either an impaired (10, 32, 38, 44) or normal (19, 22, 38) endothelium-dependent relaxation in ZO rats. Reduced ET-1-induced vasoconstriction was also observed by others in various vascular beds in diabetes (3, 26, 29, 43), hypertension (12, 13, 28), and aging (35). In contrast, several conflicting studies reported either a normal (37) or enhanced (7, 19, 24, 39–41) ET-1-induced constriction in models of diabetes. The apparent difference in ET-1 response has not been adequately explained; however, it is believed that local activity of ET-1 modulates the ETA expression, thereby influencing ET-1 response. Alternatively, these differences may, in part, be due to the differences between arterial preparation (conduit vs. resistance arteries) or age of the animals investigated (16).

We evaluated the role of ETA and ETB receptors in the ET-1 response by using specific receptor inhibitors. Inhibition of ETA significantly reduced the majority of the ET-1-induced contractions in both ZO and ZL rats, indicating that ETA primarily mediates the contraction to ET-1. Inhibition of ETB, however, enhanced the maximal contraction to ET-1 in ZO arteries, whereas ZL arteries were unaffected. This suggests that ETB primarily opposes ET-1-induced contraction only in ZO arteries but not in ZL arteries. Combined inhibition of ETA and ETB receptors reversed the ETA inhibitor-induced diminution of contraction to ET-1 in ZO arteries. In contrast, in ZL arteries, the maximal contraction to ET-1 after ETA inhibition was unaffected by the addition of ETB inhibitor. However, the EC50 of ET-1 dose response was significantly increased in both groups, suggesting modulation of ET-1 sensitivity of arteries by ETB receptors. Interestingly, inhibition of ETB receptor alone or in combination with ETA inhibition in ZO arteries restored the contraction to ET-1 and abolished the difference in ET-1 response between ZO and ZL arteries, implicating ETB receptors in the diminished ET-1 response. Thus it is likely that in ZO arteries, ETB receptor activation, possibly via enhanced NO production, may have reduced the contraction to ET-1.

We previously reported an enhanced eNOS expression and increased NO production in the coronary (22) and basilar (10) arteries from ZO rats. NO generated via ETB-receptors (5, 33) regulates ET-1 activity by inhibiting its production in vascular endothelial cells (4, 42), displacing ET-1 from receptors and reducing the [Ca2+]i mobilization in response to ET-1 (15). Therefore, it appeared important to evaluate the involvement of NO in diminishing the contraction to ET-1. Inhibition of eNOS resulted in an increase in ET-1-induced maximal contraction in ZO arteries and a leftward shift of ET-1 response curves in arteries from both groups. Similar to ETB blockade, inhibition of eNOS abolished the difference in contraction to ET-1 between ZO and ZL arteries. Taken together, ETB and eNOS inhibition studies implicate both in a concerted action to enhance the generation of NO to reduce the ET-1-induced contraction. It may be explained that elevated eNOS enzyme activity promotes enhanced NO generation in response to ETB activation, thus resulting in diminished ET-1-induced contraction in ZO arteries.

Alternatively, a decrease in expression of ETA receptors or increased expression of ETB receptors can also lead to reduced response to ET-1. It has been known that increased vascular expression and activity of ET-1 results in downregulation of ETA receptors in various disease models (12, 13) where decreased ET-1 response was observed. However, our RT-PCR studies found normal ET-1 and ETA mRNA expression in SCA of ZO compared with ZL rats. Similarly, Western blot analysis of vascular ETA receptor protein showed similar expression in both rats. Because ETB receptors may also mediate ET-1-induced contraction, we evaluated the expression of the ETB receptor mRNA in ZO and ZL arteries and found them to be similar. Thus altered expression of ETA or ETB receptors does not appear to mediate reduced ET-1 response in ZO arteries. Interestingly, Molero et al. (28) reported decreased ET-1 binding, despite normal ETA protein levels in mesenteric microvessels of DOCA-salt hypertensive rats with diminished ET-1 response. Thus normal ETA protein levels do not rule out decreased ET-1 vascular binding by an unknown mechanism, resulting in decreased ET-1 response in ZO coronary arteries.

Several studies in diabetes models reported increased VSM cell [Ca2+]i elevation as the mechanism underlying enhanced responses to ET-1 (18, 25, 31). This finding led us to evaluate whether decreased elevation of [Ca2+]i in VSM cells might precede diminished ET-1 response in ZO arteries. By using fluo-4 AM, a calcium-sensitive fluorescent dye, we found that ET-1 induced elevations of [Ca2+]i in freshly isolated VSM cells of both ZO and ZL coronary arteries at 10–9 and 10–8 M concentrations. Elevation of [Ca2+]i was followed immediately by contraction of VSM cells. Similarly, membrane depolarization by KCl also induced elevation of [Ca2+]i followed by contraction of VSM cells. VSM cells from ZO arteries, however, displayed decreased peak elevation of [Ca2+]i in response to ET at both doses tested compared with ZL arteries. In addition, the decrease in length of the VSM cells was also significantly less in ZO compared with ZL. The decreased ET-1-induced peak increase [Ca2+]i and maximal contraction in VSM cells of ZO compared with ZL persisted even after L-NAME treatment. This suggests an additional abnormal VSM contraction to ET-1 independent of endothelium.

To compare and also to verify our findings of [Ca2+]i experiments in SCAs, we performed similar experiments in VSM cells of cerebral arteries in which we observed identical ET-1-induced contraction in both groups of Zucker rats. In contrast to the SCAs, ET-1-induced [Ca2+]i elevation and contraction was found to be similar in VSM cells from cerebral arteries in ZO compared with ZL arteries. Our [Ca2+]i and contraction studies in isolated VSM cells were consistent with our previous vascular reactivity studies in basilar arteries in which we reported normal ET-1-induced contraction in ZO arteries. Interestingly, cerebral arteries and SCAs in ZO rats exhibited a fascinating variation in the underlying mechanisms of vascular dysfunction. Thus our isolated VSM cell uncovered reduced smooth muscle contraction to ET-1 in ZO in addition to the endothelial dysfunction involving the ETB receptors.

On the basis of the evidence from various pathological states with abnormal ET-1 response, the potential mechanisms of decreased ET-1-induced elevation of [Ca2+]i may include 1) decreased ET receptors on VSM cells, 2) altered expression of various Ca2+ channels, 3) decreased sensitivity of the contractile apparatus to the [Ca2+]i, or 4) uncoupling of receptor activation and [Ca2+]i influx. Western blot analysis of ETA expression and RT-PCR studies of ET-1, ETA, and ETB receptor expression clearly indicated normal receptor numbers in ZO arteries. Furthermore, we observed an identical elevation of [Ca2+]i in VSM cells of ZO and ZL arteries in response to depolarization with KCl. This intact [Ca2+]i response to KCl in ZO, though not conclusive, suggests normal nonreceptor-mediated Ca2+ mobilization. Further studies, however, are required to study the expression and to characterize the electrophysiological properties of calcium channels in ZO arteries.

Several VSM cell [Ca2+]i measurement studies in diabetic (25) and hypertensive models (34, 36) have shown that altered Ca2+ sensitivity of contractile apparatus leads to an abnormal response to ET-1. Typically, Ca2+ sensitivity was assessed by quantitating the relationship between various parameters of contraction and change in myoplasmic free [Ca2+]i. In our data analysis, we derived an arbitrary index of Ca2+ sensitivity by dividing %maximal contraction by %maximal increase in [Ca2+]i for individual VSM cells in response to ET-1. In both ZO and ZL cells, the index was close to unity, indicating a linear relationship between elevation of [Ca2+]i and contraction of VSM cells. No significant difference in the index of relationship between [Ca2+]i and contraction was observed in VSM cells from ZO and ZL arteries, suggesting that Ca2+ sensitivity was unlikely to have contributed to reduced ET-1 response. Similar to SCAs, the VSM cells from cerebral arteries also displayed identical [Ca2+]i-contractility relationship, as indicated by the arbitrary index of calcium sensitivity. Thus we report for the first time an uncoupling of receptor activation and [Ca2+]i elevation as a likely mechanism underlying the abnormal ET-1-induced contraction in SCAs of ZO rats.

Our data revealed a multitude of mechanisms underlying the diminished ET-1 response in SCAs of ZO rats that involve both endothelium and vascular smooth muscle. Increased ETB-mediated generation of NO and uncoupling of [Ca2+]i elevation from receptor activation are the likely mechanisms underlying the diminished ET-1 response in ZO arteries. Although it is unclear, the abnormal ET-1 response may be a compensatory mechanism to mitigate the pronounced vasoconstrictor burden and vascular remodeling known to occur in IR. The significance of our novel findings is that IR promotes vascular dysfunction via distinctly diverse mechanisms in the cerebral and coronary arteries of identical diameter in ZO rats.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This research was supported by National Institutes of Health Grants HL-30260, HL-50587, HL-46558, DK-62372, HL-77731, HL-65380, and HL-66074 and American Heart Association Grant 0270114N.


   ACKNOWLEDGMENTS
 
The authors appreciate the technical guidance with confocal microscopy provided by Kenneth Grant of Department of Pathology, Wake Forest University Health Sciences.


   FOOTNOTES
 

Address for reprint requests and other correspondence: D. W. Busija, Dept. of Physiology and Pharmacology, Wake Forest Univ. Health Sciences, Hanes 1050, Medical Center Blvd., Winston-Salem, NC 27157 (e-mail: dbusija{at}wfubmc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Ajayi AA, Ogungbade GO, Hercule HC, Oyekan AO, and Mutembei L. Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA2 mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats. Diabetes Res Clin Pract 63: 155–169, 2004.[CrossRef][ISI][Medline]
  2. Awazu M, Parker RE, Harvie BR, Ichikawa I, and Kon V. Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats. J Cardiovasc Pharmacol 17, Suppl 7: S500–S502, 1991.
  3. Boulanger C and Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587–590, 1990.[ISI][Medline]
  4. Cannan CR, Mathew V, and Lerman A. New insight into coronary endothelial dysfunction: role of endothelin. J Lab Clin Med 131: 300–305, 1998.[Medline]
  5. Centers for Disease Control and Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 140: 951–957, 2004.[Abstract/Free Full Text]
  6. Dumont AS, Dumont RJ, McNeill JH, Kassell NF, Sutherland GR, and Verma S. Chronic endothelin antagonism restores cerebrovascular function in diabetes. Neurosurgery 52: 653–660, 2003.[CrossRef][ISI][Medline]
  7. Erdos B, Miller AW, and Busija DW. Impaired endothelium-mediated relaxation in isolated cerebral arteries from insulin-resistant rats. Am J Physiol Heart Circ Physiol 282: H2060–H2065, 2002.[Abstract/Free Full Text]
  8. Erdos B, Snipes JA, Kis B, Miller AW, and Busija DW. Vasoconstrictor mechanisms in the cerebral circulation are unaffected by insulin resistance. Am J Physiol Regul Integr Comp Physiol 287: R1456–R1461, 2004.[Abstract/Free Full Text]
  9. Erdos B, Snipes JA, Miller AW, and Busija DW. Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 53: 1352–1359, 2004.[Abstract/Free Full Text]
  10. Erdos B, Snipes JA, Tulbert CD, Katakam PV, Miller AW, and Busija DW. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H-oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol. In press.
  11. Giulumian AD, Molero MM, Reddy VB, Pollock JS, Pollock DM, and Fuchs LC. Role of ET-1 receptor binding and [Ca2+]i in contraction of coronary arteries from DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 282: H1944–H1949, 2002.[Abstract/Free Full Text]
  12. Giulumian AD, Pollock DM, Clarke N, and Fuchs LC. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 274: R1613–R1618, 1998.[Abstract/Free Full Text]
  13. Gohla A, Schultz G, and Offermanns S. Role for G12/G13 in agonist-induced vascular smooth muscle cell contraction. Circ Res 87: 221–227, 2000.[Abstract/Free Full Text]
  14. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, and Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol 158: 485–494, 1994.[CrossRef][ISI][Medline]
  15. Hopfner RL and Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42: 1383–1394, 1999.[CrossRef][ISI][Medline]
  16. Hopfner RL, Hasnadka RV, Wilson TW, McNeill JR, and Gopalakrishnan V. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ETA receptor expression in rat aortic smooth muscle cells. Diabetes 47: 937–944, 1998.[Abstract]
  17. Hopfner RL, McNeill JR, and Gopalakrishnan V. Vanadate treatment normalizes exaggerated vascular smooth muscle responses in the obese Zucker rat. Eur J Pharmacol 357: 61–65, 1998.[CrossRef][ISI][Medline]
  18. Hopfner RL, Misurski DA, McNeill JR, and Gopalakrishnan V. Effect of sodium orthovanadate treatment on cardiovascular function in the hyperinsulinemic, insulin-resistant obese Zucker rat. J Cardiovasc Pharmacol 34: 811–817, 1999.[CrossRef][ISI][Medline]
  19. Karagiannis J, Reid JJ, Darby I, Roche P, Rand MJ, and Li CG. Impaired nitric oxide function in the basilar artery of the obese Zucker rat. J Cardiovasc Pharmacol 42: 497–505, 2003.[CrossRef][ISI][Medline]
  20. Katakam PV, Pollock JS, Pollock DM, Ujhelyi MR, and Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol 280: H522–H527, 2001.[Abstract/Free Full Text]
  21. Katakam PV, Tulbert CD, Snipes JA, Erdos B, Miller AW, and Busija DW. Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species. Am J Physiol Heart Circ Physiol 288: H854–H860, 2005.[Abstract/Free Full Text]
  22. Kis B, Snipes A, Bari F, and Busija DW. Regional distribution of cyclooxygenase-3 mRNA in the rat central nervous system. Brain Res Mol Brain Res 126: 78–80, 2004.[Medline]
  23. Lee DL and Sturek M. Endothelin-induced myoplasmic Ca2+ responses and tyrosine phosphorylation in coronary smooth muscle. J Cardiovasc Pharmacol 40: 18–27, 2002.[CrossRef][ISI][Medline]
  24. Lee DL, Wamhoff BR, Katwa LC, Reddy HK, Voelker DJ, Dixon JL, and Sturek M. Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic swine are prevented by atorvastatin. J Pharmacol Exp Ther 306: 132–140, 2003.[Abstract/Free Full Text]
  25. McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, and Johnston GD. Vasoconstriction to endogenous endothelin-1 is impaired in patients with type II diabetes mellitus. Clin Sci (Lond) 99: 175–179, 2000.[Medline]
  26. McFarlane SI, Banerji M, and Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86: 713–718, 2001.[Free Full Text]
  27. Molero MM, Giulumian AD, Reddy VB, Ludwig LM, Pollock JS, Pollock DM, Rusch NJ, and Fuchs LC. Decreased endothelin binding and [Ca2+]i signaling in microvessels of DOCA-salt hypertensive rats. J Hypertens 20: 1799–1805, 2002.[CrossRef][ISI][Medline]
  28. Nugent AG, McGurk C, Hayes JR, and Johnston GD. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes 45: 105–107, 1996.[Abstract]
  29. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, and King GL. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266: 23251–23256, 1991.[Abstract/Free Full Text]
  30. Ouchi Y, Han SZ, Kim S, Akishita M, Kozaki K, Toba K, and Orimo H. Augmented contractile function and abnormal Ca2+ handling in the aorta of Zucker obese rats with insulin resistance. Diabetes 45, Suppl 3: S55–S58, 1996.
  31. Phillips SA, Sylvester FA, and Frisbee JC. Oxidant stress and constrictor reactivity impair cerebral artery dilation in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288: R522–R530, 2005.[Abstract/Free Full Text]
  32. Pollock DM, Keith TL, and Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196–1204, 1995.[Abstract]
  33. Shaw LM, Ohanian J, and Heagerty AM. Calcium sensitivity and agonist-induced calcium sensitization in small arteries of young and adult spontaneously hypertensive rats. Hypertension 30: 442–448, 1997.[Abstract/Free Full Text]
  34. Shipley RD, and Muller-Delp JM. Aging decreases vasoconstrictor responses of coronary resistance arterioles through endothelium-dependent mechanisms. Cardiovasc Res 66: 374–383, 2005.[Abstract/Free Full Text]
  35. Smith L, Payne JA, Sedeek MH, Granger JP, and Khalil RA. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension 41: 787–793, 2003.[Abstract/Free Full Text]
  36. Stepp DW and Frisbee JC. Augmented adrenergic vasoconstriction in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 282: H816–H820, 2002.[Abstract/Free Full Text]
  37. Subramanian R and MacLeod KM. Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477: 143–152, 2003.[CrossRef][ISI][Medline]
  38. Tickerhoof MM, Farrell PA, and Korzick DH. Alterations in rat coronary vasoreactivity and vascular protein kinase C isoforms in type 1 diabetes. Am J Physiol Heart Circ Physiol 285: H2694–H2703, 2003.[Abstract/Free Full Text]
  39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998.[CrossRef][ISI][Medline]
  40. Verma S, Arikawa E, Lee S, Dumont AS, Yao L, and McNeill JH. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol 80: 980–986, 2002.[CrossRef][ISI][Medline]
  41. Wamhoff BR, Dixon JL, and Sturek M. Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia. J Vasc Res 39: 208–220, 2002.[CrossRef][ISI][Medline]
  42. Wang QD, Gonon A, Shimizu M, Sjoquist PO, and Pernow J. Contribution of endothelin to the coronary vasoconstriction in the isolated rat heart induced by nitric oxide synthase inhibition. Acta Physiol Scand 163: 325–330, 1998.[ISI][Medline]
  43. Wu SQ, Hopfner RL, McNeill JR, Wilson TW, and Gopalakrishnan V. Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 45: 994–1000, 2000.[Abstract/Free Full Text]
  44. Zanchi A, Delacretaz E, Taleb V, Gaillard R, Jeanrenaud B, Brunner HR, and Waeber B. Endothelial function of the mesenteric arteriole and mechanical behavior of the carotid artery in rats with insulin resistance and hypercholesterolaemia. J Hypertens 13: 1463–1470, 1995.[ISI][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. Sachidanandam, M. M. Elgebaly, A. K. Harris, J. R. Hutchinson, E. M. Mezzetti, V. Portik-Dobos, and A. Ergul
Effect of chronic and selective endothelin receptor antagonism on microvascular function in Type 2 diabetes
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2743 - H2749.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S.-J. Kim, X. Zhang, X. Xu, A. Chen, J. B. Gonzalez, S. Koul, K. Vijayan, G. J. Crystal, S. F. Vatner, and T. H. Hintze
Evidence for enhanced eNOS function in coronary microvessels during the second window of protection
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2152 - H2158.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/1/R145    most recent
00405.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Busija, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Busija, D. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.